Research

Energy balance

Semaglutide would be cost-effective at a threshold of $120,000 per QALY gained if the annual cost were lowered by 18% to $7,055.

Reducing the cost of semaglutide could enhance its affordability and accessibility for patients.

StrongSupportsmedium confidence
Semaglutide would be cost-effective at a threshold of $120 000 per QALY gained if the annual cost were lowered an additional 18% to $7055.
Susan Hennessy et al. · JAMA Cardiology · 2026

Why this rating

Based on a population-based cohort simulation study design.

Source

Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults

Susan Hennessy et al. · JAMA Cardiology · 2026

DOI 10.1001/jamacardio.2025.5243

cohort · n=4000000Cited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →